Hormonal
Liraglutide treatment improves beta-cell function (measured by C-peptide and HOMA-B) and reduces the proinsulin-to-insulin ratio compared to placebo when added to metformin and TZD.
If you are taking metformin and a TZD for Type 2 Diabetes, adding liraglutide (1.2 or 1.8 mg once daily) can help your pancreas work better by improving beta-cell function. This is measured by markers like C-peptide and the proinsulin-to-insulin ratio. While this is a technical benefit, it contributes to better overall blood sugar control.
Significant increases in C-peptide and homeostasis model assessment of β-cell function and significant decreases in the proinsulin-to-insulin ratio occurred with liraglutide versus placebo.
Why this rating
Large-scale, double-blind, placebo-controlled, randomized trial.
Source
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al. · Diabetes Care · 2009
DOI 10.2337/dc08-2124
More from this paper
- Adding liraglutide (1.2 or 1.8 mg/day) to maximized metformin and thiazolidinedione (TZD) therapy significantly improves glycemic control (A1C, fasting, and postprandial glucose) and induces dose-dependent weight loss in patients with type 2 diabetes.Strong
- Liraglutide treatment in combination with metformin and TZD leads to significant reductions in systolic blood pressure and favorable changes in lipid profiles (specifically free fatty acids, LDL, and triglycerides) compared to placebo.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →